Shopping Cart
- Remove All
Your shopping cart is currently empty
CCG-1423
🥰Excellent
Catalog No. T2014Cas No. 285986-88-1
Alias CCG1423
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
CCG-1423
🥰Excellent
Purity: 99.98%
Catalog No. T2014Alias CCG1423Cas No. 285986-88-1
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | 30 € | In Stock | |
| 10 mg | 49 € | In Stock | |
| 25 mg | 92 € | In Stock | |
| 50 mg | 156 € | In Stock | |
| 100 mg | 261 € | In Stock | |
| 200 mg | 406 € | In Stock | |
| 500 mg | 660 € | In Stock | |
| 1 mL x 10 mM (in DMSO) | 47 € | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CCG-1423"
Azathioprine
Cited
BW 57-322
T1237446-86-6
Azathioprine (BW 57-322), an immunosuppressive agent, inhibits purine synthesis and GTP-binding protein Rac1 activation.
- 42 €
Size
QTY
CitedCASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- 30 €
Size
QTY
Ketoconazole Cited
Xolegel, R-41400, Extina, (±)-Ketoconazol
T067965277-42-1
Ketoconazole (R-41400), a CYP3A4 inhibitor, is an imidazole anti-fungal agent.
- 31 €
Size
QTY
CitedSalirasib
S-Farnesylthiosalicylic acid, FTS, Farnesyl Thiosalicylic Acid
T6163162520-00-5
Salirasib (Farnesyl Thiosalicylic Acid)(Ki=2.6 μM), an effective competitive prenylated protein methyltransferase (PPMTase) inhibitor, inhibits Ras methylation with potential antineoplastic activity.
- 28 €
Size
QTY
GNE-7915
GNE7915
T19451351761-44-8
GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.
- 37 €
Size
QTY
(S)-(-)-Perillyl alcohol
T828218457-55-1
(S)-(−)-Perillyl alcohol (Perillyl alcohol), a monoterpene found in lavender, inhibits Ras farnesylation, upregulates the mannose-6-phosphate receptor, induces apoptosis, and exhibits anti-cancer activity.
- 29 €
Size
QTY
SKLB-163
SKLB163
T261931255099-06-9In house
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
- 130 €
Size
QTY
CCG-257081
MRTF/SRF-IN-1, CCG257081, CCG 257081
T307781922098-90-5In house
CCG-257081 (MRTF/SRF-IN-1) is an inhibitor of cardiac myosin-related transcription factor and serum response factor (MRTF/SRF) that acts by inhibiting the Rho/MRTF/SRF pathway.CCG-257081 has shown efficacy in preventing bleomycin-induced fibrosis in several mouse models. CCG-257081 can be used in cancer prevention and fibrosis research.
- 122 €
Size
QTY
RMC6236
T746982765081-21-6
RMC-6236 is a potent RAS(ON)MULTI inhibitor with broad-spectrum inhibitory activity against RAS-GTP and can be used in cancer research.
- 282 €
Size
QTY
Deltarasin
T64621440898-61-2In house
Deltarasin is a small molecular inhibitor of KRAS-PDEδ interaction with Kd of 38 nM for binding to purified PDEδ.
- 36 €
Size
QTY
LRRK2 inhibitor 1
T118781802525-61-6In house
LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
- 64 €
Size
QTY
Zoledronic Acid Cited
Zometa, Zoledronate, ZOL 446, CGP42446A, CGP 42446
T6739118072-93-8
Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
- 30 €
Size
QTY
CitedSelect Batch
Purity:99.98%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription. |
| Targets&IC50 | LRRK2 (G2019S):1.85 nM, LRRK2 (WT):1.28 nM |
| In vivo | In H9c2 cells, CCG-1423 inhibits MRTF nuclear localization and completely blocks the activity of STARS proximal reporter genes. It also suppresses TGF-β-induced fibrogenesis in human colon myofibroblasts. Under the influence of CCG-1423 and LY294002, mouse embryonic stem cells differentiate into the mesendoderm. In melanoma cells (A375M2 and SK-Mel-147) overexpressing RhoC, CCG-1423 selectively inhibits cell proliferation. |
| Cell Research | Cells in normal culture medium are plated (2,000 per well) in a 96-well plate coated with laminin. After attachment, the medium is replaced with serum-free medium (0% FBS) with 30 μmol/L LPA with or without 300 nM CCG-1423. Fresh LPA with or without CCG-1423 is added at day 5 to ensure that LPA and compound are present throughout the experiment. On day 8, WST-1 reagent is added to the wells for 1 h and absorbance at 450 nm is read using a Victor plate reader.(Only for Reference) |
| Alias | CCG1423 |
| Molecular Weight | 454.75 |
| Formula | C18H13ClF6N2O3 |
| Cas No. | 285986-88-1 |
| Smiles | CC(ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 4 mg/mL (8.79 mM), Heating is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 83 mg/mL (182.5 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy CCG-1423 | purchase CCG-1423 | CCG-1423 cost | order CCG-1423 | CCG-1423 chemical structure | CCG-1423 in vivo | CCG-1423 formula | CCG-1423 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.